Stock ALRN AILERON THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Aileron Therapeutics, Inc.

Equities

ALRN

US00887A2042

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-06-07 pm EDT 		5-day change 1st Jan Change
3.24 USD -1.52% Intraday chart for Aileron Therapeutics, Inc. +1.25% +6.28%
May. 16 Aileron Therapeutics, Inc. Announces Chief Financial Officer Changes CI
May. 16 Aileron Therapeutics, Inc. Announces Executive Changes CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
AQ
Aileron Therapeutics to Present at Two Upcoming Investor Conferences
AQ
Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million
AQ
Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million
AQ
Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
AQ
Aileron Therapeutics : Corporate Presentation April 2024
PU
Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
AQ
Aileron Therapeutics : Management Change/Compensation - Form 8-K
PU
Aileron Therapeutics Announces CEO Transition
AQ
Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event
AQ
Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024
AQ
Aileron Therapeutics : Merger Announcement
PU
Aileron Therapeutics Announces Acquisition of Lung Therapeutics
PR
AILERON THERAPEUTICS INC Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
AILERON THERAPEUTICS INC Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)
AQ
AILERON THERAPEUTICS INC : Costs Associated with Exit or Disposal Activities, Other Events (form 8-K)
AQ
Aileron Therapeutics Announces Termination of Phase 1b Breast Cancer Chemoprotection Trial and Exploration of Strategic Alternatives
AQ
Aileron Therapeutics Regains Compliance with Nasdaq Listing Requirements
AQ
AILERON THERAPEUTICS INC : Material Modification to Rights of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)
AQ
Aileron Therapeutics Announces a 1-for-20 Reverse Stock Split
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALRN Stock
  4. News Aileron Therapeutics, Inc.
  5. Press Releases